TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37142335
Drug: Maternal lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal lipid-based nutrient supplement initiated preconceptionally (arm 1, n=217)
Study: 37142335
Drug: Maternal lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal lipid-based nutrient supplement initiated at 12 weeks gestation (arm 2, n=230)
Study: 37142372
Drug: Tucatinib monotherapy
Normalized name: tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tucatinib monotherapy (cohort C)
Study: 37142474
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily opioid dose in morphine milligram equivalents (MME)
Study: 37142543
Drug: Hematopoietic stem
Normalized name: Umbilical Cord Blood Hematopoietic Stem Cells
DrugBank: Umbilical Cord Blood Hematopoietic Stem Cells (DB15723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematopoietic stem cell transplantation (standard treatment)
Study: 37142543
Drug: Gene addition
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene addition therapy
Study: 37142730
Drug: Gemcitabine-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine-based treatment (n=99)
Study: 37142733
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose antibiotic (IIIrd gen cephalosporin) administered within 30-min of POEM
Study: 37142733
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose antibiotic (IIIrd gen cephalosporin) administered for a total of three days
Study: 37142733
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose antibiotic (IIIrd gen cephalosporin)
Study: 37142733
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose antibiotic (IIIrd gen cephalosporin)
Study: 37143003
Drug: Blended Forensic
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended Forensic Outpatient Systemic Therapy (FASTb)
Study: 37143003
Drug: Regular Forensic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular Forensic Outpatient Systemic Therapy (FASTr)
Study: 37143128
Drug: Single application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single application of selective serotonin reuptake inhibitor (SSRI) or serotonin-noradrenaline reuptake inhibitor (SNRI)
Study: 37143128
Drug: SSRI/SNRI combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI/SNRI combined with quetiapine (≥ 150 mg/day)
Study: 37143154
Drug: MR-guided online
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR-guided online adaptive radiotherapy (RT) with concurrent chemotherapy, conventionally fractioned RT with isotoxic dose escalation up to 70 Gy, online plan adaptation performed once weekly or in case of major anatomical changes.
Study: 37143154
Drug: MR-guided online
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR-guided online adaptive radiotherapy (RT) with concurrent chemotherapy.
Study: 37143158
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (surgery followed by conventional radiotherapy after 1-2 weeks)
Study: 37143685
Drug: Ruxolitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib plus simvastatin (5 mg BID for 7 days followed by 10 mg BID for 7 days and 40 mg once a day for 14 days)
Study: 37143998
Drug: PACAP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PACAP infusion for 20 min
Study: 37143998
Drug: VIP infusion
Normalized name: VIP
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP infusion for 20 min
Study: 37143999
Drug: Intra-arterial TNK
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial TNK (4 mg) followed by TNK (0.4 mg/min for 20 min) during EVT
Study: 37144634
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.14 g·kg -1 ·d -1)
Study: 37144820
Drug: CushMed (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: CushMed (16 patients treated with stable cortisol-lowering drug dosage)
Study: 37145134
Drug: Nd:YAG/Er:YAG dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG/Er:YAG dual laser therapy (4 treatments, 1-2 months apart)
Study: 37145134
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid application (6 months)
Study: 37145134
Drug: Nd:YAG/Er:YAG dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG/Er:YAG dual laser therapy
Study: 37145134
Drug: Nd:YAG/Er:YAG dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG/Er:YAG dual laser therapy and Topical steroid application
Study: 37145169
Drug: ONC201 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 and paxalisib (combination)
Study: 37145975
Drug: Zanubrutinib co-administered
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib co-administered with rifabutin
Study: 37146180
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake of 235 (133, 401) μg/day
Study: 37146180
Drug: Iodine intake
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine intake >400 μg/day
Study: 37146180
Drug: Long-term iodine
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term iodine intake >400 μg/day
Study: 37146444
Drug: StayWell text
Approvals — FDA: no, EMA: no, PMDA: no
Description: StayWell text messaging intervention (60-day program based on cognitive behavioral therapy)
Study: 37146752
Drug: Durvalumab 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 20 mg/kg plus tremelimumab 1 mg/kg administered intravenously every 4 weeks for four doses, followed by up to nine doses of durvalumab monotherapy every 4 weeks for up to 12 months or until disease progression
Study: 37146874
Drug: Acceptance-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-based behavioral therapy (ABBT) plus treatment-as-usual (TAU)
Study: 37147083
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza vaccine (LAIV) administration
Study: 37147201
Drug: 3-antigen vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-antigen vaccine (PreHevbrio™)
Study: 37147201
Drug: Single-antigen vaccine
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-antigen vaccine (Engerix-B)
Study: 37147301
Drug: Midostaurin added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin added to intensive chemotherapy in late group (2016-2020)
Study: 37147642
Drug: Oral dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dronabinol (BX-1) once daily before bedtime for 10 weeks
Study: 37147642
Drug: Oral dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dronabinol (BX-1)
Study: 37147667
Drug: Integrated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated cognitive behavioral treatment (ICBT)
Study: 37147708
Drug: Depression (defined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depression (defined as a score of ≥ 10 on the PHQ-9) among participants using illicit drugs in the last month
Study: 37147725
Drug: Rapid outreach
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid outreach following missed doses as detected by an electronic adherence monitoring device
Study: 37147725
Drug: Weekly check-in
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly check-in texts
Study: 37147725
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of adherence monitoring and support components
Study: 37147739
Drug: Home-based transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based transcranial direct current stimulation (tDCS) administered by caregivers under remote supervision.
Study: 37148183
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure therapy (PAP)
Study: 37148183
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for insomnia plus positive airway pressure (CBT-I+PAP)
Study: 37148249
Drug: Litifilimab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Litifilimab (monoclonal antibody against BDCA2)
Study: 37148266
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + 0.12% chlorhexidine gluconate mouthrinse twice a day for 3 mo + rubber interproximal bristle cleaners twice a day for 6 mo
Study: 37148266
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + oral hygiene instructions (Control)
Study: 37148266
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + 0.12% chlorhexidine gluconate mouthrinse twice a day for 3 mo + rubber interproximal bristle cleaners twice a day for 6 mo (in subjects with diabetes)
Study: 37148831
Drug: Heated high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated high-flow nasal cannula (HFNC) therapy
Study: 39374601
Drug: Once-weekly insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly insulin icodec
Study: 39270686
Drug: Once-daily insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily insulin degludec
Study: 37149257
Drug: Rehabilitation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation group (exercise-based rehabilitation program consisting of two weekly sessions of physical exercise for 8 weeks and one educational session)
Study: 37149701
Drug: Low-dose tamoxifen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tamoxifen (2.5, 5 mg)
Study: 37149701
Drug: High-dose tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tamoxifen (10, 20 mg)
Study: 37149701
Drug: Tamoxifen (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (any dose)
Study: 37150144
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals (DAAs) treatment
Study: 37150147
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to gliadin (AGA IgG)
Study: 37150258
Drug: Fractionated brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated brain radiation therapy (RT)
Study: 37150411
Drug: Oral intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake
Study: 37150895
Drug: Extended-release melatonin
Normalized name: melatonin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release melatonin (4 mg)
Study: 37150895
Drug: Immediate-release melatonin
Normalized name: melatonin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release melatonin (4 mg)
Study: 37150952
Drug: Deucravacitinib (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib (once-daily oral pill)
Study: 37150952
Drug: Placebo (inactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactive pill)
Study: 37150952
Drug: Apremilast (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast (twice-daily oral pill)
Study: 37151105
Drug: 12-month testosterone
Normalized name: testosterone 12.5 MG/ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month testosterone replacement therapy (TRT)
Study: 37151571
Drug: Mindfulness meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness meditation and auricular acupuncture (CIH therapies)
Study: 37151894
Drug: Urine kidney
Normalized name: URINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine kidney injury molecule 1 (uKIM-1)
Study: 37152360
Drug: vixotrigine 200
Normalized name: Vixotrigine
DrugBank: Vixotrigine (DB11706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vixotrigine 200 mg BID
Study: 37152360
Drug: vixotrigine 350
Normalized name: Vixotrigine
DrugBank: Vixotrigine (DB11706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vixotrigine 350 mg BID
Study: 37152361
Drug: INTEP-AR model
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INTEP-AR model (large Infarct, NIHSS score, Thrombolysis, Endovascular treatment, Pneumonia, brain Atrophy, and Recanalisation)
Study: 37152367
Drug: Saline irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline irrigation (100 ml saline pulse irrigation after cholangiography)
Study: 37153087
Drug: Bee venom
Normalized name: Bee venom
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bee venom (BV) phonophoresis with conservative treatment of medical ulcer care
Study: 37153087
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment of medical ulcer care with ultrasound sessions only (control)
Study: 37153587
Drug: serplulimab 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: serplulimab 4.5 mg/kg plus nab-paclitaxel 260 mg/m² for up to 2 years (35 dosing cycles)
Study: 37153702
Drug: Intranasal OXT
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal OXT (Syntocinon, 40 USP units/mL, 4 IU/spray, 16 to 24 IU 3 times daily at mealtimes)
Study: 37153770
Drug: Low-dose combined
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combined olanzapine and sertraline
Study: 37154020
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral rivaroxaban daily for 35 days
Study: 37154608
Drug: Stromal Cells,
Normalized name: ALLOGENEIC-UNRELATED PLACENTA-DERIVED STROMAL CELLS, EXPANDED EX VIVO
DrugBank: Cenplacel-L (DB19188)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stromal Cells, details on dosage and duration not available
Study: 37155164
Drug: Pharmacogenetics-informed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetics-informed treatment (PIT) with TCAs (nortriptyline, clomipramine, or imipramine) based on CYP2D6 and CYP2C19 genotypes.
Study: 37155164
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment with standard initial TCA dosage.
Study: 37155164
Drug: Pharmacogenetics-informed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetics-informed treatment (PIT)
Study: 37155171
Drug: Intravenous Ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Ketamine plus Digital Training
Study: 37155168
Drug: Whole-body hypothermia
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body hypothermia (reduction of rectal temperatures to between 33.0 °C and 34.0 °C for 72 hours)
Study: 37155168
Drug: Control (rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (rectal temperatures maintained between 36.0 °C and 37.0 °C)
Study: 39711430
Drug: Anlotinib plus
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib plus PD-1 inhibitor
Study: 37156249
Drug: Sintilimab plus
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus IBI305 plus chemotherapy (pemetrexed and cisplatin)
Study: 37156249
Drug: Sintilimab plus
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus IBI305 plus chemotherapy
Study: 39374601
Drug: Once-daily insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily insulin glargine U100
Study: 37156466
Drug: Enoxaparin 1
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 mg/kg (up to 100 mg)
Study: 37156466
Drug: Weight categories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight categories (≤90 kg: 40 mg; 91-130 kg: 60 mg; 131-170 kg: 80 mg; >170 kg: 100 mg)
Study: 37156551
Drug: Transgenic adoptive
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transgenic adoptive cell therapy (ACT) with NY-ESO-1-specific TCR transgenic lymphocytes, NY-ESO-1 peptide-pulsed dendritic cell (DC) vaccination, and nivolumab-mediated PD-1 blockade
Study: 37156588
Drug: Shortened antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortened antibiotic treatment of 5 days
Study: 37156588
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment of 7 days or longer
Study: 37158010
Drug: Vaccine willingness
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine willingness
Study: 37158083
Drug: Lipid-lowering therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy, details not available
Study: 37158447
Drug: Calibrated blood-collection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calibrated blood-collection drape and treatment bundle (uterine massage, oxytocic drugs, tranexamic acid, intravenous fluids, examination, and escalation)
Study: 37158447
Drug: Calibrated blood-collection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calibrated blood-collection drape and treatment bundle
Study: 37158780
Drug: Virtual 'Coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual 'Coping with Brain Fog' intervention, details on dosage and duration not available
Study: 37158831
Drug: Rifapentine 10
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 10 mg/kg for 17 or 26 weeks
Study: 37158831
Drug: Rifapentine 15
Normalized name: rifapentine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifapentine 15 mg/kg for 17 or 26 weeks
Study: 37158831
Drug: Rifapentine 20
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 20 mg/kg for 17 or 26 weeks
Study: 37158831
Drug: Standardized six-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized six-month treatment regimen (rifampicin, isoniazid, pyrazinamide, ethambutol for 26 weeks)
Study: 37158911
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray plus an oral antidepressant (ESK + AD)
Study: 37158911
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray plus an oral antidepressant (AD + PBO)
Study: 37158925
Drug: Probiotics treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics treatment for 12 weeks
Study: 37158965
Drug: Site-specific HCV
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Site-specific HCV treatment workflows utilizing direct-acting antivirals (DAAs) and a simplified treatment algorithm.
Study: 37158965
Drug: Training of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training of providers on the use of a simplified HCV treatment algorithm with DAAs.
Study: 37159035
Drug: Amoxicillin-clavulanate combined
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate combined with prednisolone
Study: 37159195
Drug: Lactulose ingestion
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose ingestion (20 g) during a continuous 10-hour sodium d3-acetate intravenous infusion
Study: 37159251
Drug: Red Bull
Normalized name: acid red 35
DrugBank: Pantothenic acid (DB01783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Bull energy drink (250 mL administered 2 hours postoperatively and for breakfast and lunch on postoperative day 1, totaling 750 mL per 24 hours)
Study: 37159251
Drug: Still water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Still water (250 mL administered 2 hours postoperatively and for breakfast and lunch on postoperative day 1, totaling 750 mL per 24 hours)
Study: 37159264
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside (NR) 1,000 mg/day
Study: 37159264
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ10) 1,200 mg/day
Study: 37160281
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (1.8 × 10^6 or 2.7 × 10^6 doses administered via direct venous inoculation at 8-week intervals)
Study: 37160396
Drug: Ride-on-toy navigation
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ride-on-toy navigation training (RNT) programme, provided 4-5 times/week for 30-45 min/session over 6 weeks, in addition to conventional therapy.
Study: 37160396
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy alone during the 6-week control phase.
Study: 37160822
Drug: Pharmacologic strategies
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic strategies (acetaminophen and ibuprofen)
Study: 37161345
Drug: Self-administered computerized
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered computerized mental health screening tool
Study: 37161377
Drug: Single-dose MR-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose MR-guided partial breast irradiation (PBI) with a prescribed dose of 20 Gy to the tumor and 15 Gy to the surrounding breast tissue.